Microbiota Replacement Therapies: Innovation in Gastrointestinal Care
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
There has been an increasing interest in the association between human disease and altered gut microbiota, and therapeutics to modulate microbiota to treat disease. Healthy human gastrointestinal microbiota is highly diverse and rich, and harbors between 500 and 2,000 species. Diseases associated with dysbiotic microbiota include antibiotic‐associated diarrhea, Clostridium difficile infection, multidrug‐resistant organisms, inflammatory bowel disease, obesity, metabolic syndrome, diabetes mellitus, neuropsychiatric diseases, and systemic autoimmune diseases. Microbiota replacement therapies have shown immense promise in treatment of recurrent C. difficile infection and are being studied for other indications. Microbiota replacement therapies for indications other than C. difficile infection should be performed only in research settings. There is an immense need for standardized microbiota replacement therapies for C. difficile infection. Studies are needed to elucidate long‐term safety and adverse events from these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“After a 10-week period of initial follow-up, 81% of patients in the FMT group had resolution with one infusion and 94% with two infusions, compared with 31% receiving vancomycin alone and 23% receiving vancomycin and bowel lavage.(29) A recent trial done in the United States, for patients with recurrent CDI, demonstra…”
ResultVrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Immunopathogenesis of IBD: current state of the art
de Souza, H. S. P., & Fiocchi, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.186 · Cited by 1,551
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 2×
“There was a donor effect seen where one of the donors had a significantly higher remission rate compared to other donors.(69) In contrast, another similar trial did not show a difference between donor and autologous FMT to induce remission in ulcerative colitis.”
BackgroundResultEuropean consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207 · cited 17×
“These include if related donor or household contacts should be preferred over standard donors, how often should donors be screened, and what should be included in standard screening.(50) Commonly used donor exclusion criteria and testing are outlined in Table 1.”
BackgroundMethodInfluentialKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002 · cited 1×
“Patients with IBS have decreased microbial diversity compared to healthy controls.(73) Treatments aimed at altering gut microbiota such as antibiotics, probiotics, and case series of FMT have been described in IBS patients.”
BackgroundRossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 1×
“In contrast, another similar trial did not show a difference between donor and autologous FMT to induce remission in ulcerative colitis.(70) In a more contemporary trial from Australia, patients with ulcerative colitis received multidonor FMT with pooled donor stool, with one colonoscopic infusion followed by enemas,…”
ResultKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695 · cited 1×
“Interestingly, in one small case series of five CDI patients, transfer of sterile filtrates from donor stool was sufficient to eliminate symptoms, suggesting that components other than bacteria, such as host secretions or microbial metabolites, may be sufficient or an alternative approach.(27)”
Background
Cited by
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
The Super-Donor Phenomenon in Fecal Microbiota Transplantation
Wilson, B. C., Vatanen, T., Cutfield, W. S., & O'Sullivan, J. M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00002 · Cited by 413
Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex
Rizzetto, L., Fava, F., Tuohy, K. M., & Selmi, C. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.008 · Cited by 331
Intestinal microbiota in early life and its implications on childhood health
Zhuang, L., Chen, H., Zhang, S., Zhuang, J., Li, Q., & Feng, Z. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.10.002 · Cited by 219
“Furthermore, this therapy has been proven to be able to reconstitute a normally functioning microbial community [162,181,186,187].”
BackgroundThe role of gut microbiota in Clostridium difficile infection
Samarkos, M., Mastrogianni, E., & Kampouropoulou, O. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.02.006 · Cited by 75
“The rationale behind FMT, or microbiota replacement therapy, is straightforward: stools from normal donors have the appropriate composition of microbiota, and when introduced in the gut, they can restore the disrupted microbiota of patients with CDI [53].”
Background
Metadata
- Authors
- Khanna, S.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-11-14
- Volume
- 103
- Issue
- 1
- Pages
- 102-111
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2765877077
- Cited by
- 62
- References
- 23
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. https://app.cochat.ai/papers/10.1002/cpt.923
- The paper
- Khanna, S. (2018). Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.923
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.